Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253635 | 0.79 | HSD17B10 (0.41) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL6385841 | 0.78 | HPGD (0.41) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL6036888 | 0.78 | HSD17B10 (0.39) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL1244870 | 0.78 | TSHR (0.48) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL8637918 | 0.78 | HSD17B10 (0.40) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL721648 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2 | |
| SCHEMBL2161442 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL7924277 | 0.78 | POLB (0.46) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL10817480 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL8112329 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627213-B1 | ANTIFRICTION BEARING PROVIDED WITH POLYMER ELECTRONICS | SCHAEFFLER TECHNOLOGIES AG (DE) | 2012-03-14 | — | — | EP | claimed |
| US-7827871-B2 | Antifriction bearing provided with polymer electronics | SCHAEFFLER KG (DE) | 2010-11-09 | — | — | US | claimed |
| US-7742281-B2 | Solid electrolytic capacitor | SANYO ELECTRIC CO., LTD. (JP) | 2010-06-22 | — | — | US | claimed |
| US-20070277612-A1 | Antifriction Bearing Provided With Polymer Electronics | Schaeffler Technologies AG & Co. KG (DE) | 2007-12-06 | — | — | US | claimed |
| US-7827871-B2 | Antifriction bearing provided with polymer electronics | SCHAEFFLER KG (DE) | 2010-11-09 | — | — | US | disclosed |
| US-7742281-B2 | Solid electrolytic capacitor | SANYO ELECTRIC CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20080158783-A1 | SOLID ELECTROLYTIC CAPACITOR | SANYO ELECTRIC CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20070277612-A1 | Antifriction Bearing Provided With Polymer Electronics | Schaeffler Technologies AG & Co. KG (DE) | 2007-12-06 | — | — | US | disclosed |
| EP-1827427-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| EP-1824480-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-08-29 | — | — | EP | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| WO-2006061376-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL D0PAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061377-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2A, HTR2C, HTR1A | ALDH1A1 1222/4885HSD17B10 2973/4885CYP2A6 658/4885 |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | ALDH1A1 1420/4885HSD17B10 2642/4885CYP2A6 688/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | ALDH1A1 1420/4885HSD17B10 2642/4885CYP2A6 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.